Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Jefferies Financial Group

Thermo Fisher Scientific (NYSE:TMO) was upgraded by Jefferies Financial Group to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

TMO has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Citigroup lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Barclays cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Finally, Wells Fargo & Company set a $683.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $625.55.

Thermo Fisher Scientific Trading Up 0.6%

NYSE TMO opened at $469.27 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.53 and a current ratio of 1.53. The company has a market capitalization of $174.39 billion, a price-to-earnings ratio of 25.80, a price-to-earnings-growth ratio of 2.41 and a beta of 0.97. The company’s 50-day simple moving average is $499.11 and its two-hundred day simple moving average is $549.52. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter in the previous year, the firm earned $5.15 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts forecast that Thermo Fisher Scientific will post 24.71 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by insiders.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the business. Boston Trust Walden Corp lifted its stake in Thermo Fisher Scientific by 35.9% during the 1st quarter. Boston Trust Walden Corp now owns 59,772 shares of the medical research company’s stock valued at $29,380,000 after acquiring an additional 15,799 shares during the period. Heritage Investors Management Corp lifted its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Heritage Investors Management Corp now owns 56,987 shares of the medical research company’s stock valued at $28,011,000 after acquiring an additional 554 shares during the period. KPP Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 1.8% during the 1st quarter. KPP Advisory Services LLC now owns 4,340 shares of the medical research company’s stock valued at $2,133,000 after acquiring an additional 77 shares during the period. Eagle Bluffs Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 3.4% during the 1st quarter. Eagle Bluffs Wealth Management LLC now owns 4,416 shares of the medical research company’s stock valued at $2,173,000 after acquiring an additional 147 shares during the period. Finally, Reliant Investment Management LLC lifted its stake in Thermo Fisher Scientific by 1.1% during the 1st quarter. Reliant Investment Management LLC now owns 12,095 shares of the medical research company’s stock valued at $5,945,000 after acquiring an additional 135 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat expectations — Thermo Fisher reported $5.44 adjusted EPS vs. ~$5.25 consensus and revenue of $11.01B (up ~6.2% y/y), showing the company still delivered above-street top- and bottom-line results. Reuters: Thermo Fisher posts quarterly results beat
• Positive Sentiment: Full-year guidance updated — Management set FY2026 EPS guidance of $24.64–$25.12 and raised its outlook, which supports longer-term earnings visibility even if organic growth is uneven. Yahoo: Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Analyst reactions mixed but generally constructive — Several firms kept buy/outperform ratings while trimming targets (Stifel: $700->$600; Robert W. Baird: $653->$639), signaling continued confidence in the company’s fundamentals despite the pullback. Benzinga / The Fly: PT cuts
• Neutral Sentiment: Analyst voices emphasize long-term opportunity — Some analysts (e.g., TD Cowen, William Blair) reiterated Buy ratings, pointing to core growth drivers and structural demand (biopharma services, lab products) that support recovery later in the year. TipRanks: Analyst commentary
• Negative Sentiment: Market punished the stock on weak underlying growth and mixed segments — Despite the beat, investors focused on muted organic growth in the core business and uneven segment performance, which triggered a sharp intraday decline and premarket weakness. Yahoo: Why TMO Stock Is Nosediving
• Negative Sentiment: Broader sector & market pressure amplified the move — The mixed report pressured peers (e.g., 10x Genomics) and coincided with a softer tape for health care/tech stocks, adding to downward momentum. Yahoo: Peer impact (10x Genomics)

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.